Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms

Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, Jackisch C, Marme F, Keller K, Hörner M, Goossens C, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Radosa JC, Banys-Paluchowski M, Wöckel A, Harbeck N, Stickeler E, Bartsch R, Aktas B, Schneeweiss A, Ettl J, Taran FA, Janni W, Würstlein R, Lux MP (2025)

Publication Type: Journal article, Review article

Publication year: 2025

Journal

Geburtshilfe und Frauenheilkunde Georg Thieme Verlag

Book Volume: 85

Pages Range: 507-519

Journal Issue: 5

DOI: 10.1055/a-2515-2366

Abstract

The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe Katharina Keller Department of Obstetrics and Gynaecology Manuel Hörner Department of Obstetrics and Gynaecology Chloe Goossens Department of Obstetrics and Gynaecology

Involved external institutions

ClinSol GmbH & Co.KG DE Germany (DE) HELIOS Kliniken DE Germany (DE) Agaplesion Markus Krankenhaus DE Germany (DE) Universitätsklinikum Augsburg DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Klinikum der Universität München DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Klinikverbund Allgäu DE Germany (DE) Universitätsklinikum Freiburg DE Germany (DE) Universitätsklinikum Ulm DE Germany (DE) St. Vincenz-Krankenhaus DE Germany (DE) Universitätsklinikum Düsseldorf DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Diakonissen-Stiftungs-Krankenhaus Speyer DE Germany (DE) Kliniken Essen-Mitte DE Germany (DE) Universitätsklinikum Mannheim DE Germany (DE) Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Immanuel Klinik Märkische Schweiz DE Germany (DE) Marienhospital Bottrop DE Germany (DE) Universitätsklinikum Tübingen DE Germany (DE) Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen DE Germany (DE) Medizinische Universität Wien AT Austria (AT) Universität Leipzig DE Germany (DE)

How to cite

APA:

Lüftner, D., Kolberg, H.C., Hartkopf, A.D., Fehm, T.N., Welslau, M., Müller, V.,... Lux, M.P. (2025). Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms. Geburtshilfe und Frauenheilkunde, 85(5), 507-519. https://doi.org/10.1055/a-2515-2366

MLA:

Lüftner, Diana, et al. "Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms." Geburtshilfe und Frauenheilkunde 85.5 (2025): 507-519.

BibTeX: Download